Ocumetics Technology Corp (OTC) Price & Analysis

Compare

25 Followers

OTC Stock Chart & Stats

C$0.55

C$0.02(6.45%)

At close: Jan 08 4:00 PM EST

C$0.55

C$0.02(6.45%)

Day’s Range― - ―

52-Week RangeC$0.26 - C$1.99

Previous CloseN/A

Volume36.17K

Average Volume (3M)77.99K

Market Cap

C$24.71M

Enterprise ValueC$25.57M

Total Cash (Recent Filing)C$905.41K

Total Debt (Recent Filing)C$4.92M

Price to Earnings (P/E)―

Beta0.52

Next Earnings

Apr 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding52,564,106

10 Day Avg. Volume70,232

30 Day Avg. Volume77,988

Financial Highlights & Ratios

PEG Ratio0.59

Price to Book (P/B)-18.55

Price to Sales (P/S)0.00

P/FCF Ratio-14.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Progress & Near-term FundingCommitted financing and early clinical signals materially reduce near-term development execution risk. A ~ $2.9M private placement plus a collaboration to optimize lens delivery supports continued trials and device refinement, helping de-risk regulatory pathways and sustain development momentum over the next several months.

Focused Ophthalmic Device PlatformA concentrated product strategy on intraocular lens technology creates a clear commercial path if trials succeed. Specialization in ophthalmology can support clinical expertise, targeted R&D, and potential IP protection, preserving a durable market position in a procedure-driven medical device niche.

Disciplined Cash ConversionFree cash flow closely tracking net loss indicates management converts reported losses into actual cash outflows predictably, and TTM FCF improvement shows some operational control. This discipline can extend runway per dollar raised and improve capital efficiency during continued development.

Bears Say

No Revenue / Unproven CommercializationThe company reports no revenue and sustained multi-million dollar losses, indicating it has not commercialized products. Without operational sales, long-term value depends entirely on clinical and regulatory success, making future cash needs and dilution risk structural constraints on growth.

Negative Equity And Rising LeverageDeeply negative equity and increased debt materially weaken financial flexibility. Higher leverage elevates refinancing and covenant risk, limits capacity to absorb trial cost overruns, and increases dependence on external capital, pressuring long-term solvency if commercial milestones are delayed.

Sustained Operating Cash BurnConsistently negative operating cash flow signals ongoing cash burn from R&D and operations. Persistent outflows reduce runway and raise the probability of dilutive financings; without near-term revenue, continued trial and development costs create a structural funding dependency.

Ocumetics Technology Corp News

Ocumetics Extends Debenture Forbearance and Closes $1.02 Million LIFE Financing

Ocumetics Technology Corp ( ($TSE:OTC) ) has issued an announcement. Ocumetics Technology Corp. has secured a forbearance agreement...

12d ago

Ocumetics De-Risks Accommodating Lens Platform With Strong First-in-Human Results

Ocumetics Technology Corp ( ($TSE:OTC) ) has shared an announcement. Ocumetics Technology Corp. reported positive three-month postoperative results...

20d ago

Ocumetics Seeks Debenture Forbearance and Warrant Incentive to Extend $4 Million Financing

An announcement from Ocumetics Technology Corp ( ($TSE:OTC) ) is now available. Ocumetics Technology Corp. has proposed a...

23d ago

Ocumetics Replaces Chief Medical Officer Role With Scientific Advisory Committee Ahead of Pivotal Trial

Ocumetics Technology Corp ( ($TSE:OTC) ) just unveiled an announcement. Ocumetics Technology Corp., a leader in next-generation ophthalmic...

1M ago

Ocumetics Raises Over $1 Million to Advance First-in-Human Clinical Trials

Ocumetics Technology Corp ( ($TSE:OTC) ) has issued an update. Ocumetics Technology Corp. has closed the first tranche...

2M ago

Ocumetics Amends Terms of Brokered Financing to Raise Up to $2.9 Million

An announcement from Ocumetics Technology Corp ( ($TSE:OTC) ) is now available. Ocumetics Technology Corp. has amended the...

2M ago

Ocumetics and Medicel Collaborate on Enhanced Lens Delivery System

Ocumetics Technology Corp ( ($TSE:OTC) ) has shared an update. Ocumetics Technology Corp. has announced an optimized lens...

3M ago

Ocumetics Technology Corp. Launches $2.5 Million Private Placement to Fund Clinical Trials

Ocumetics Technology Corp ( ($TSE:OTC) ) has provided an announcement. Ocumetics Technology Corp. has announced a brokered private...

3M ago

Ocumetics Reports Promising Early Results in Intraocular Lens Study

Ocumetics Technology Corp ( ($TSE:OTC) ) has provided an announcement. Ocumetics Technology Corp. announced promising one-month results from...

4M ago

Ocumetics to Showcase Innovative Lens Technology at Bahamas Summit

An announcement from Ocumetics Technology Corp ( ($TSE:OTC) ) is now available. Ocumetics Technology Corp. announced its participation...

4M ago

OTC FAQ

What was Ocumetics Technology Corp’s price range in the past 12 months?

Ocumetics Technology Corp lowest stock price was C$0.26 and its highest was C$1.99 in the past 12 months.

What is Ocumetics Technology Corp’s market cap?

Ocumetics Technology Corp’s market cap is C$24.71M.

When is Ocumetics Technology Corp’s upcoming earnings report date?

Ocumetics Technology Corp’s upcoming earnings report date is Apr 28, 2026 which is in 64 days.

How were Ocumetics Technology Corp’s earnings last quarter?

Ocumetics Technology Corp released its earnings results on Nov 24, 2025. The company reported -C$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.011.

Is Ocumetics Technology Corp overvalued?

According to Wall Street analysts Ocumetics Technology Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ocumetics Technology Corp pay dividends?

Ocumetics Technology Corp does not currently pay dividends.

What is Ocumetics Technology Corp’s EPS estimate?

Ocumetics Technology Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ocumetics Technology Corp have?

Ocumetics Technology Corp has 52,564,106 shares outstanding.

What happened to Ocumetics Technology Corp’s price movement after its last earnings report?

Ocumetics Technology Corp reported an EPS of -C$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.111%.

Which hedge fund is a major shareholder of Ocumetics Technology Corp?

Currently, no hedge funds are holding shares in TSE:OTC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ocumetics Technology Corp

Ocumetics Technology Corp., a research and product development company, designs and produces various lenses. Its products include Bionic Lens, an expandable intraocular lens that fits within the natural lens compartment of the eye to eliminate the need for corrective lenses. The company is headquartered in Calgary, Canada.